Welcome, Guest. Please login or register.
October 04, 2023, 11:30:36 am

Login with username, password and session length

  • Total Posts: 55101
  • Total Topics: 4848
  • Online Today: 102
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 102
Total: 102


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: CVS Study: 1 in 12 Don't Adhere to Sovaldi Treatment  (Read 4793 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
CVS Study: 1 in 12 Don't Adhere to Sovaldi Treatment
« on: September 23, 2014, 10:59:30 am »
While it's not surprising that people are adhering less to hep C treatment in the real world than in closely monitored clinical studies, here's something to note:

More than 8 percent of patients taking Sovaldi (sofosbuvir), the latest hepatitis C virus drug from Gilead Sciences, do not complete the full 12-week course of treatment.

So far, pharmacy data collected by CVS over the past nine months shows that the dropout rate has been roughly four times that observed in clinical trials.

Read more: http://www.hepmag.com/articles/cvs_sovaldi_adherence_study_2831_26200.shtml


© 2023 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.